Publications by authors named "James Dru"

Claim this Profile
M
Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
Sanjeev Kumar, Eugene Y Tan, Georgy Hartmann, Zachary Biddle, Arthur J Bergman, James Dru

Drug Metab Dispos· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Thomas C Marbury, Bo Jin, Deborah Panebianco, M Gail Murphy, Hong Sun, James Dru

Anesth Analg· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
Rajesh Krishna, Arthur J Bergman, Bo Jin, Amit Garg, Brad Roadcap, James Dru

J Clin Pharmacol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
Kenneth C Lasseter, Jay Gambale, Bo Jin, Art Bergman, Marvin Constanzer, James Dru

J Clin Pharmacol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of aprepitant on the pharmacokinetics of intravenous midazolam.
Anup K Majumdar, Kerri X Yan, Diana V Selverian, Suna Barlas, Marvin Constanzer, James Dru

J Clin Pharmacol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.
Anup K Majumdar, Jacqueline B McCrea, Deborah L Panebianco, Michael Hesney, James Dru

Clin Pharmacol Ther· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis